Correction: Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial

• 期刊论文

• 发表日期：

  2026年3月19日

• Dalong Zhu,
• Jianhua Ma,
• Weimin Wang,
• Bimin Shi,
• Xiaolin Dong,
• Fang Bian,
• Qingju Li,
• Yihua Wang,
• Chengyan Jiang,
• Xueying Wang,
• Kun Wang,
• Hongwei Ling,
• Xiaoxia Shi,
• Zhifeng Cheng,
• Guoyue Yuan,
• Liping Li,
• Xiuhai Su,
• Yibing Lu,
• Weihong Song,
• Yawei Zhang,
• Wen Hu,
• Xin Zhang,
• Haifang Wang,
• Yu Liu,
• Jifang Li,
• Lili Zhang,
• Yan Liu,
• Xiaokun Sun,
• Xiaoyue Wang,
• Keqin Zhang,
• Yongcai Zhao,
• Lili Zhang,
• Tianrong Pan,
• Ping Li,
• Shu Li,
• Haifeng Zhou,
• Chengxia Jiang,
• Xin Zheng,
• Lin Ni,
• Bo Feng,
• Feng Li,
• Lianshan Piao,
• Hongwei Jin,
• Yang Liu,
• Hongyi Cao,
• Yufeng Li,
• Hanqing Cai,
• Hong Mao,
• Yongqian Liang,
• Jianchao Guo,
• Yangang Wang,
• Yan Li,
• Ning Xu,
• Jinan Zhang,
• Qiu Zhang,
• Wuyan Pang,
• Jianxin Yu,
• Yulong Xu,
• Yue Zhou,
• Yiming Li,
• Qinghua Wang